AQP5 has been shown to activate EGFR and consequently to induce the MAPK signaling pathway in several types of cancer, such as glioma [39], lung adenocarcinoma [53,74], colon cancer [38], and also pancreatic cancer [19]. This evidence concerns the gene EGFR and central nervous system cancer.